Cempra ($CEMP) managed to break onto the public market with an IPO in February, with a pipeline of next-generation antibiotics that addresses the growing threat of resistance to existing antibacterial drugs. Prabhavathi Fernandes, Cempra's president and CEO, says she's optimistic about biotech IPOs this year. "I think the quality may be better this year," Fernandes said. "Last year, a lot of companies went public because they didn't have other funding options." Cempra excluded, of course.